United Therapeutics Corporation has signed an agreement with DEKA Research & Development Corp to continue the development of a breakthrough technology for the subcutaneous delivery of the Remodulin (treprostinil) Injection.

The device is expected to offer a potential treatment option for patients who suffer from pulmonary arterial hypertension (PAH) and improve administration of Remodulin.